Arrowstreet Capital Limited Partnership Has $58.79 Million Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Arrowstreet Capital Limited Partnership boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 142,192 shares of the company’s stock after buying an additional 8,617 shares during the period. Arrowstreet Capital Limited Partnership owned approximately 0.17% of IDEXX Laboratories worth $58,788,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IDXX. FSA Wealth Management LLC acquired a new position in shares of IDEXX Laboratories in the 3rd quarter valued at $25,000. Rialto Wealth Management LLC acquired a new position in IDEXX Laboratories in the fourth quarter valued at about $30,000. Retirement Wealth Solutions LLC bought a new position in IDEXX Laboratories during the fourth quarter worth about $31,000. Kestra Investment Management LLC acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth about $38,000. Finally, Crews Bank & Trust bought a new stake in shares of IDEXX Laboratories in the 4th quarter valued at about $41,000. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Price Performance

NASDAQ IDXX opened at $418.57 on Wednesday. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $548.88. The firm’s 50 day moving average is $436.90 and its 200-day moving average is $441.45. The company has a market capitalization of $33.93 billion, a PE ratio of 39.23, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.11% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on IDXX shares. Barclays increased their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Piper Sandler boosted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, March 25th. Morgan Stanley cut their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Finally, Bank of America increased their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.